Southwest Securities: CXO industry revenues are recovering season by season, but the demand for preclinical services still needs to be restored.

From a short-term perspective, commercial orders continue to be digested, putting pressure on the apparent performance of CDMO; overseas mature CXO clinical pipelines are steadily advancing, and the preclinical demand still needs to be restored.

Zhitong FinanceNov 26 01:00 ET

Trending Industry Today: WUXI APPTEC Leads Losses In Biotechnology Stocks

Moomoo NewsNov 22 02:50 ET

Trending Industry Today: PHARMARON Leads Losses In CRO Stocks

Moomoo NewsNov 22 02:40 ET

Wuxi Bio (02269): Miao Jingwen has been appointed as a non-executive director.

Wuxi Bio (02269) announced that effective from November 20, 2024: Dr. Wu Yibing has resigned from his position as...

Zhitong FinanceNov 20 06:26 ET

Contract research organizations concept rises, Joinn Laboratories (06127) rises by 5.11%, institutions say CXO sector is expected to benefit from the recovery of overseas research and development demand.

Jinwu Financial News | The concept of contract research organizations has risen across the board, with joinn laboratories (06127) up 5.11%, tigermed (03347) up 4.33%, frontage (01521) up 2%, pharmaron (03759) up 1.84%, and wuxi bio (02269) up 0.79%. Zhongtai reported that the bank believes that as the medical insurance fund prepayment system continues to deepen and improve, and the supporting DRG/DIP system is continuously implemented in various provinces and cities, the long-term "triangle debt" relationship among hospitals, pharmaceutical companies, and medical insurance persists, and the "zero markup policy on pharmaceuticals" compresses hospital profitability.

Golden Guard Financial NewsNov 19 21:46 ET

Trending Industry Today: WUXI APPTEC Leads Losses In CRO Stocks

Moomoo NewsNov 14 01:30 ET